Aptorum Group and DiamiR Biosciences Announce Two Abstracts Accepted for Presentation at CTAD 2025 Conference
ByAinvest
Wednesday, Nov 19, 2025 8:02 am ET1min read
APM--
DiamiR Biosciences and Aptorum Group announced two poster presentations at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference. The presentations highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration. The studies were funded by the Small Business Innovation Research Grant from the National Institute on Aging. The merger between Aptorum Group and DiamiR Biosciences is expected to close in the first quarter of 2026.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet